Jury finds Johnson & Johnson must pay $8B in Risperdal case
Johnson & Johnson, still reeling from settling two Ohio opioid-related lawsuits for more than $20 million, was slapped with an $8 billion judgment Tuesday over its antipsychotic drug Risperdal. A jury in Philadelphia, according to legal web site Law360, hit the drug giant with the staggering payout “after agreeing the company had recklessly ignored the risks that the antipsychotic drug Risperdal could lead to breast growth in adolescent boys as it pushed the medication for use in children.” The drug comes from a J&J subsidiary, Janssen Pharmaceuticals Inc. The judgment came about on behalf of Nicholas Murray, a Maryland resident who grew breasts after he started using Risperdal as a nine-year-old in 2003 to help control symptoms related to autism.
Johnson & Johnson, still reeling from settling two Ohio opioid-related lawsuits for more than $20 million, was slapped with an $8 billion judgment Tuesday over its antipsychotic drug Risperdal. A jury in Philadelphia, according to legal web site Law360, hit the drug giant with the staggering payout “after agreeing the company had recklessly ignored the risks that the antipsychotic drug Risperdal could lead to breast growth in adolescent boys as it pushed the medication for use in children.” The drug comes from a J&J subsidiary, Janssen Pharmaceuticals Inc. The judgment came about on behalf of Nicholas Murray, a Maryland resident who grew breasts after he started using Risperdal as a nine-year-old in 2003 to help control symptoms related to autism.
No hay comentarios:
Publicar un comentario